PGE2 Elevates IL-23 Production in Human Dendritic Cells via a cAMP Dependent Pathway

Mediators Inflamm. 2015:2015:984690. doi: 10.1155/2015/984690. Epub 2015 Aug 27.

Abstract

PGE2 elevates IL-23 production in mouse dendritic cells while inhibits IL-23 production in isolated human monocytes. Whether this differential effect of PGE2 on IL-23 production is cell-type- or species-specific has not been investigated in detail. The present study was designed to investigate the effect of PGE2 on IL-23 production in human DCs and the possible underlying mechanisms. Human monocytes derived dendritic cells (Mo-DCs) were pretreated with or without PGE2. Then the cells were incubated with zymosan. Our results demonstrated that PGE2 promoted zymosan-induced IL-23 production in a concentration dependent manner. In addition, it was found that PGE2 is also able to elevate MyD88-mediated IL-23 p19 promoter activity. More importantly, ELISA data demonstrated that db-cAMP, a cAMP analog, and forskolin, an adenylate cyclase activator, can mimic the effect of PGE2 on zymosan-induced IL-23 production, and rp-cAMP, a protein kinase A (PKA) inhibitor, can block the effect of PGE2. Moreover, PGE2 can increase zymosan-induced expression of the mRNA levels of both p19 and p40 subunits, which was mimicked by db-cAMP and forskolin. Our data suggest that PGE2 elevates the production of IL-23 in human Mo-DCs via a cAMP dependent pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cells, Cultured
  • Cyclic AMP / metabolism*
  • Dendritic Cells / drug effects
  • Dendritic Cells / metabolism*
  • Dinoprostone / pharmacology*
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Interleukin-23 / genetics
  • Interleukin-23 / metabolism*
  • Monocytes / drug effects
  • Monocytes / metabolism
  • Promoter Regions, Genetic / genetics
  • Reverse Transcriptase Polymerase Chain Reaction
  • Zymosan / pharmacology

Substances

  • Interleukin-23
  • Zymosan
  • Cyclic AMP
  • Dinoprostone